Deletion 11q is an important prognostic factor1
Del 11q occurs in about 20% of patients with CLL1
- It is associated with extensive lymphadenopathy, rapid disease progression, and poor survival1
Changes in iwCLL Guidelines2,3
|Baseline testing for 11q deletion|
|iwCLL 2018||iwCLL 2008|
Bolding indicates updates.
CLL=chronic lymphocytic leukemia, Del=deletion, iwCLL=International Workshop on Chronic Lymphocytic Leukemia.
Other CLL biomarkers
What other genetic markers can provide prognostic value?
References: 1. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916. 2. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. 3. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
Share this page